Search research articles
Contact Us
Filters
Showing results (61-70 of 511) with videos related to
Page
of 52
Sort By:
Clinical Lung Cancer
|
July 19, 2021
Dorian Gray Syndrome of Upfront Immunotherapy in Patients With Non-Small-Cell Lung Cancer and High PD-L1 Expression
Lizza E L Hendriks, Jordi Remon, Benjamin Besse
Bulletin Du Cancer
|
May 15, 2026
Radon and lung cancer
Edouard Auclin, Maxime Janin, Laura Mezquita, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 14, 2023
Does perioperative immunotherapy reduce the risk of second primary cancers?
Marco Tagliamento, Jordi Remon, David Planchard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2021
Paving the Way for Long-Term Survival in Non-Small-Cell Lung Cancer
Jordi Remon, Lizza E L Hendriks, Benjamin Besse
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 28, 2019
Immune-Related Adverse Events and Outcomes in Patients with Advanced Non-Small Cell Lung Cancer: A Predictive Marker of Efficacy?
Jordi Remon, Noemí Reguart, Edouard Auclin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2013
ERCC1 and RRM1: ready for prime time?
Benjamin Besse, Ken A Olaussen, Jean-Charles Soria
Immunotherapy
|
July 31, 2019
Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?
Elie Rassy, Laura Mezquita, Jordi Remon, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 26, 2017
Peritoneal recurrence of thymoma treated by surgery and hyperthermic intraperitoneal chemotherapy
Camille Mazza, Jordi Remon, Charles Honoré, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 10, 2019
Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact?
Arnaud Bayle, Benjamin Besse, Maxime Annereau, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 1, 2023
Are we ready to escalate or de-escalate immune treatment strategies in NSCLC based on liquid biopsy data?
Jordi Remon, Alvaro Lopez, David Planchard, et al.
Page
of 52
Search research articles
Search
Showing results (61-70 of 511) with videos related to
Sort By:
Page
of 52
Clinical Lung Cancer
|
July 19, 2021
Dorian Gray Syndrome of Upfront Immunotherapy in Patients With Non-Small-Cell Lung Cancer and High PD-L1 Expression
Lizza E L Hendriks, Jordi Remon, Benjamin Besse
Bulletin Du Cancer
|
May 15, 2026
Radon and lung cancer
Edouard Auclin, Maxime Janin, Laura Mezquita, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 14, 2023
Does perioperative immunotherapy reduce the risk of second primary cancers?
Marco Tagliamento, Jordi Remon, David Planchard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2021
Paving the Way for Long-Term Survival in Non-Small-Cell Lung Cancer
Jordi Remon, Lizza E L Hendriks, Benjamin Besse
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 28, 2019
Immune-Related Adverse Events and Outcomes in Patients with Advanced Non-Small Cell Lung Cancer: A Predictive Marker of Efficacy?
Jordi Remon, Noemí Reguart, Edouard Auclin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2013
ERCC1 and RRM1: ready for prime time?
Benjamin Besse, Ken A Olaussen, Jean-Charles Soria
Immunotherapy
|
July 31, 2019
Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?
Elie Rassy, Laura Mezquita, Jordi Remon, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 26, 2017
Peritoneal recurrence of thymoma treated by surgery and hyperthermic intraperitoneal chemotherapy
Camille Mazza, Jordi Remon, Charles Honoré, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 10, 2019
Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact?
Arnaud Bayle, Benjamin Besse, Maxime Annereau, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 1, 2023
Are we ready to escalate or de-escalate immune treatment strategies in NSCLC based on liquid biopsy data?
Jordi Remon, Alvaro Lopez, David Planchard, et al.
Page
of 52